All doses of the diabetes and weight management injectable tirzepatide (Mounjaro, Zepbound) were taken off the FDA's shortage ...

Eli Lilly & Co plans to invest £279 million ($364 million) in a new initiative to support UK biotechs along with a study of ...

Some patients fear that they’ll lose access to tirzepatide because the US Food and Drug Administration determined that a ...

Mounjaro, the brand name for tirzepatide, is a drug that treats type 2 diabetes by lowering blood sugar levels. According to ...

In this randomized controlled trial, in patients with both moderate-severe obstructive sleep apnea (OSA) and obesity, it was ...

Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Harris is seeing an uptick in support from Black women voters who support her efforts to protect abortion and expand prenatal ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold ...

These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...

With an estimated 2 million people in the United States taking copycat vers | A compounding industry group has sued the FDA, ...

As prices for Ozempic have risen in recent months, many people may be seeking cheaper alternatives for managing diabetes or ...